Article

VIDEO: Thomas Stinchcombe, MD, Discusses the Treatment of Non-Small Cell Lung Cancer

Conference|NAMCP: National Association of Managed Care Physicians Forum

Thomas Stinchcombe, MD, assistant professor of clinical research, UNC Lineberg Comprehensive Cancer Center, discusses the treatment of patients with non-small cell lung cancer (NSCLC).

Thomas Stinchcombe, MD, assistant professor of clinical research, UNC Lineberg Comprehensive Cancer Center, discusses the treatment of patients with non-small cell lung cancer (NSCLC). In order to manage cost, Dr Stinchcombe says that molecular testing allows clinicians to pick the correct treatment for the patient.

This video was taken on November 8 at the NAMCP Fall Managed Care Forum in Las Vegas, NV.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Martin Engelke
Dr Adela Perolla
Dr Adela Perolla | Image Credit: - stock.adobe.com
Dr Ola Landgren
Dr Ola Landgren
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Brian Slomovitz
Dr Ola Landgren
Dr Brian Slomovitz
Related Content
The timing of initiation to immunotherapy, either with the first cycle of chemotherapy or within 21 days of diagnosis, does not significantly affect outcomes in ES-SCLC. | Image Credit: Bonsales - stock.adobe.com
June 12th 2025

Immunotherapy Timing Does Not Significantly Affect Outcomes in ES-SCLC

Jared Kaltwasser
The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC), a study found.
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com
June 6th 2025

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

Rose McNulty
Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the CHALLENGE study recommended.
Managed Care Cast.
June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia
On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
young adult cancer | Image credit: Roswell Park Cancer Center
June 6th 2025

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

Mary Caffrey
Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50. Obesity is among the factors linked to rising rates of cancer in young adults.
The findings support the use of luspatercept as the first-line standard of care for anemia treatment in patients with MDS. | Image Credit: wanchalerm - stock.adobe.com
June 5th 2025

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

Rose McNulty
Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo